Population Pharmacokinetic Analyses for Rezafungin (CD101) Efficacy Using Phase 1 Data

Invasive Candidiasis

(2016)   NEW ENGLAND JOURNAL OF MEDICINE

Population Pharmacokinetic Analysis for a Single 1,200-Milligram Dose of Oritavancin Using Data from Two Pivotal Phase 3 Clinical Trials

(2015) C. M. Rubino et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Epidemiology and Risk Factors for Echinocandin NonsusceptibleCandida glabrataBloodstream Infections: Data From a Large Multisite Population-Based Candidemia Surveillance Program, 2008–2014

(2015) Snigdha Vallabhaneni et al.   Open Forum Infectious Diseases

Population Pharmacokinetic Analyses for BC-3781 Using Phase 2 Data from Patients with Acute Bacterial Skin and Skin Structure Infections

(2014) C. M. Rubino et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Role of FKS Mutations in Candida glabrata: MIC Values, Echinocandin Resistance, and Multidrug Resistance

(2014) Cau D. Pham et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Population Pharmacokinetics of Escalating Doses of Caspofungin in a Phase II Study of Patients with Invasive Aspergillosis

(2013) Gudrun Würthwein et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Changes in Incidence and Antifungal Drug Resistance in Candidemia: Results From Population-Based Laboratory Surveillance in Atlanta and Baltimore, 2008-2011

(2012) A. A. Cleveland et al.   CLINICAL INFECTIOUS DISEASES

The evolution of haploidy and diploidy

(2008) Sarah P. Otto et al.   CURRENT BIOLOGY